NYMOX Provides Current Update
September 13, 2022 09:30 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with...
NYMOX Updates Shareholders
July 15, 2022 09:30 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding progress in the Company business activities....
NYMOX Receives Deficiency Letter from NASDAQ
July 14, 2022 12:18 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports that on July 7, 2022 the Company received a deficiency letter from NASDAQ stating that the...
NYMOX Receives RTF letter from FDA
May 23, 2022 08:30 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at...
Nymox Announces Closing of $6.4 Million Financing
April 04, 2022 09:45 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has closed its $6.4 million financing announced in...
Nymox Announces $5 Million Registered Direct Offering
March 18, 2022 08:30 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited...
NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
March 03, 2022 11:00 ET
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New Drug...
Nymox Shareholder Update
December 13, 2021 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has completed all the Company’s required...
NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference
November 15, 2021 11:39 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today that it will be presenting at the Torrey Hills...
NYMOX Provides Current Update
October 11, 2021 10:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today a one-month update to shareholders as a...